Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Organisation › Details

Transgene S.A. (Euronext: TNG)

Transgene is a France-based biopharmaceutical company focused on the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The Company has four compounds in Phase II clinical trials: TG4010, JX594/TG6006, TG4001/RG3484 and TG4040 and one compound in Phase I clinical trial: TG4023. Transgene has entered into strategic collaborative agreements for the development of two of its immunotherapy products: - An option agreement with Novartis for an exclusive license to develop TG4010 for the treatment of various cancers, including non small cell lung cancer (NSCLC) - An in-licensing agreement with US-based Jennerex Biotherapeutics, Inc., to develop and market JX594 (JX594/TG6006), an oncolytic product. Transgene has bio-manufacturing capacities for viral-based vectors. *

 

Period Start 1979-01-01 established
  Group Mérieux (Group)
Products Industry therapeutic vaccine
  Industry 2 immunotherapy
Person Person Archinard, Philippe (Transgene 200512 CEO)
     
Region Region Strasbourg
  Country France
  Street Boulevard Gonthier d’Andernach
  City 67405 Illkirch
  Tel +33-3-8827-9100
    Address record changed: 2018-07-24
     
Basic data Employees D: 101 to 500 (2006-12-31)
  Currency EUR
  Annual sales 28,019,000 (revenues, total (2007) 2007-12-31)
  Profit -5,521,000 (2007-12-31)
  Cash 84,100,000 (2014-09-30)
     
    * Document for �About Section�: Transgene S.A.. (3/31/11). "Press Release: Transgene Announces Completion of Enrolment in HCVac (Phase II Trial) of TG4040 for the Treatment of Chronic Hepatitis C". Illkirch.
     
   
Record changed: 2017-10-15

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Mérieux (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2018 Boston Partnering 560x80px




» top